18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)

NCT04647214 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 220

Last updated 2025-08-03

No results posted yet for this study

Summary

Study to collect effectiveness and safety data after administration of a bimatoprost intracameral implant in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Conditions

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • ALLERGAN INC. · Allergan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-03
Primary Completion
2024-07-12
Completion
2024-07-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04647214 on ClinicalTrials.gov